Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012
WELWYN GARDEN CITY, England and BOSTON, March 15, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Business Officer, Barry Kenny , will present overview of the Company at 09:45am CET on Tuesday 20 March 2012 at the 6th Annual BIO-Europe Spring international partnering conference. The presentation will take place in room E107, Level 1.
BIO-Europe Spring, which is produced by EBD Group, is taking place at the Amsterdam RAI Convention Center in Amsterdam, the Netherlands on 19-21 March 2012.
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically un-druggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, anxiety, chronic insomnia, addiction and diabetes. For more information, please visit http://www.heptares.com.
Contact Information
Citigate Dewe Rogerson
Mark Swallow , Chris Gardner
+44(0)20-7282-2948
mark.swallow@citigatedr.co.uk
Heptares Therapeutics Ltd
Malcolm Weir , Chief Executive Officer (UK)
+44(0)1707-358-629
Malcolm.weir@heptares.com
Dan Grau , President (USA)
+1-857-222-4586
dan.grau@heptares.com
SOURCE Heptares Therapeutics
More by this Source
Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
Apr 29, 2013, 04:00 ET
Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
Apr 16, 2013, 06:32 ET
Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
Apr 02, 2013, 10:21 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.